BibTex format
@article{Quraishi:2025:ecco-jcc/jjae189,
author = {Quraishi, MN and Cheesbrough, J and Rimmer, P and Mullish, BH and Sharma, N and Efstathiou, E and Acharjee, A and Gkoutus, G and Patel, A and Marchesi, JR and Camuzeaux, S and Chappell, K and Valdivia-Garcia, MA and Ferguson, J and Brookes, MJ and Walmsley, M and Rossiter, AE and van, Schaik W and McInnes, RS and Cooney, R and Trauner, M and Beggs, AD and Iqbal, TH and Trivedi, PJ},
doi = {ecco-jcc/jjae189},
journal = {Journal of Crohn's and Colitis},
title = {Open Label Vancomycin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Improved Colonic Disease Activity and Associations With Changes in Host–Microbiome–Metabolomic Signatures},
url = {http://dx.doi.org/10.1093/ecco-jcc/jjae189},
volume = {19},
year = {2025}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>We conducted a single-arm interventional study, to explore mucosal changes associated with clinical remission under oral vancomycin (OV) treatment, in primary sclerosing cholangitis-associated inflammatory bowel disease (PSC-IBD); NCT05376228.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>Fifteen patients with PSC and active colitis (median fecal calprotectin 459 µg/g; median total Mayo score 5) were treated with OV (125 mg QID) for 4 weeks and followed-up for a further 4 weeks of treatment withdrawal (8 weeks, end-of-study). Colonic biopsies were obtained at baseline and Week 4. Clinical assessments, and serum and stool samples (metagenomics, metatranscriptomics, and metabolomics) were collected at Weeks 0, 2, 4, and 8. The primary efficacy outcome measure was the induction of clinical remission.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Oral vancomycin resulted in clinical remission in 12/15 patients and significant reductions in fecal calprotectin. Oral vancomycin was associated with reduced abundances of Lachnospiraceae, genera Blautia and Bacteroides; and enrichment of Enterobacteriaceae, and genera Veillonella, Akkermansia, and Escherichia. Oral vancomycin treatment was associated with the downregulation of multiple metatranscriptomic pathways (including short-chain fatty acid [SCFA] metabolism and bile acid [BA] biotransformation), along with host genes and multiple pathways involved in inflammatory responses and antimicrobial defence; and an upregulation of genes associated with extracellular matrix repair. Oral vancomycin use r
AU - Quraishi,MN
AU - Cheesbrough,J
AU - Rimmer,P
AU - Mullish,BH
AU - Sharma,N
AU - Efstathiou,E
AU - Acharjee,A
AU - Gkoutus,G
AU - Patel,A
AU - Marchesi,JR
AU - Camuzeaux,S
AU - Chappell,K
AU - Valdivia-Garcia,MA
AU - Ferguson,J
AU - Brookes,MJ
AU - Walmsley,M
AU - Rossiter,AE
AU - van,Schaik W
AU - McInnes,RS
AU - Cooney,R
AU - Trauner,M
AU - Beggs,AD
AU - Iqbal,TH
AU - Trivedi,PJ
DO - ecco-jcc/jjae189
PY - 2025///
SN - 1873-9946
TI - Open Label Vancomycin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Improved Colonic Disease Activity and Associations With Changes in Host–Microbiome–Metabolomic Signatures
T2 - Journal of Crohn's and Colitis
UR - http://dx.doi.org/10.1093/ecco-jcc/jjae189
UR - https://doi.org/10.1093/ecco-jcc/jjae189
VL - 19
ER -